BWAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brainsway Ltd (BWAY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive analyst ratings, and innovative product developments in the mental health space make it a compelling investment opportunity. Despite the lack of immediate trading signals, the long-term growth potential outweighs short-term technical concerns.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD histogram is below 0 and negatively contracting, suggesting weak momentum. RSI is neutral at 66.223, and the price is trading near resistance levels (R1: 12.754, R2: 13.187). Overall, the technical setup is moderately positive but not strongly bullish.
Recent FDA premarket approval for Neurolief's Proliv RX system, enhancing the company's product portfolio.
Strong clinical results for the SWIFT™ accelerated Deep TMS protocol, showing high response and remission rates for Major Depressive Disorder.
Analysts have raised price targets significantly, with a consensus target of $30, indicating confidence in the company's growth potential.
Revenue, Net Income, and EPS have shown substantial YoY growth in the latest quarter.
Lack of significant hedge fund or insider trading activity, indicating neutral sentiment from institutional investors.
MACD and RSI indicators do not show strong momentum, which could limit short-term price movements.
No recent congress trading data or significant political endorsements.
In Q3 2025, Brainsway achieved a 28.66% YoY revenue increase to $13.51M, a 136.56% YoY net income increase to $1.57M, and a 100% YoY EPS growth to $0.04. Gross margin improved to 75.19%, up 2.27% YoY, reflecting strong operational efficiency and profitability.
Analysts are highly bullish on BWAY, with recent upgrades in price targets from $24 to $30 by H.C. Wainwright and Northland. Analysts highlight the company's FDA-approved SWIFT protocol and strategic partnerships as key drivers for long-term growth.
